In oligometastatic castration-resistant prostate cancer, the rationale to use local SBRT is improved disease control.

—As more men are cured of prostate cancer, or are long-term survivors, the challenges of survivorship are in the spotlight. Improved screening practices, earlier detection, and better therapies have ...

Docetaxel added to androgen deprivation therapy (ADT) was the most cost-effective first-line regimen for patients with ...

Men with prostate cancer who were treated with the GnRH agonist leuprolide had significantly more coronary artery plaque progression than those receiving the GnRH antagonist relugolix.

ADT with injectable gonadotropin-releasing hormone (GnRH) receptor agonists such as leuprolide has been associated with cardiovascular morbidity, and cardiovascular disease is the leading cause of ...

J&J JNJ announced that the European Commission has approved its precision therapy, Akeega (niraparib and abiraterone acetate dual action tablet), for expanded use in prostate cancer. The regulatory ...

Researchers have found in a new study that among men with prostate cancer undergoing androgen deprivation therapy, use of oxybutynin 5 mg twice daily significantly reduced the frequency ...

PSMA-617 to androgen deprivation therapy (ADT) with androgen receptor pathway inhibitor (ARPI) bettered disease control in patients with metastatic hormone-sensitive prostate cancer (mHSPC), according ...

Prostate cancer is the most common cancer in men throughout the United States. Most men do not realize they have cancer due ...